Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Switching from propylene glycol to glycerin in topical finasteride may reduce systemic absorption and side effects while maintaining local scalp DHT suppression. Concerns exist about glycerin's ability to deliver the full dose to hair follicles.

Pelage plans to release PP405 trial results at a medical meeting in early 2026, possibly during the AAD conference in March. There is speculation about whether new hair loss treatments or GTA 6 will be released first.

Hair loss treatments, including PP405, minoxidil, finasteride, and RU58841, with hopes for future solutions. Participants discuss the emotional impact of hair loss and consider alternatives like hair transplants or acceptance.

PP405 shows promise in stimulating new terminal hair growth by activating dormant follicles, with no systemic adverse effects observed in a short-term trial. However, long-term efficacy remains unproven, and further trials are needed to confirm its potential as a hair loss treatment.

PP405 is discussed as a potential treatment for growing a beard in patchy areas, with some users suggesting minoxidil as an alternative. Experiences with minoxidil vary, with some users reporting significant beard growth and others seeing minimal results.

The conversation discusses the potential availability and use of the pp405 molecule for hair loss treatment, with concerns about its legitimacy and safety on the grey market. Participants also mention using products from Umbrella Labs and discuss the concentration and production costs of pp405.

A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.

A user is seeking recommendations for purchasing Minichek 5% solution, a PG-free minoxidil, due to a contact allergy to propylene glycol. They are looking for an affordable option comparable in price to Kirkland or Amazon brand minoxidil.

The conversation is about using a dermastamp for hair loss treatment and concerns about a potentially scam product, pp405. It suggests sticking with known treatments like finasteride and minoxidil.

Finasteride and Dutasteride can be obtained cheaply through Amazon One Medical with an Rx Pass subscription for $20/year. Users discuss various options and costs for hair loss treatments, including Blink Health and Mark Cuban's pharmacy.

Dutasteride can be obtained more affordably through Amazon's RxPass program or telehealth services like Dr. B, with some users also mentioning options like Cost Plus Drugs and Miiskin for prescriptions. Users discuss switching from finasteride to dutasteride and mention additional treatments like minoxidil.

PP405 is in phase 2 trials for hair loss, with discussions on its cost and effectiveness compared to minoxidil and finasteride. Users are skeptical about its efficacy and timeline, with hopes for market release by 2027.

The conversation discusses the pros and cons of using propylene glycol versus ethyl alcohol in topical solutions for finasteride and minoxidil. It questions why propylene glycol is commonly used and whether ethyl alcohol might be a better option.

The user is considering RU58841 and has been using dutasteride since age 17. They are seeking affordable SARD options, mentioning ASC-J9, GT20029, and AH001.

The conversation discusses the potential effectiveness and future results of the hair loss treatment pp405, with questions about its impact on different hair loss stages and areas. There is anticipation for phase 3 trial results to provide more data, and hope that pp405 could enhance hair transplant outcomes.

The conversation is about hair loss treatments, specifically setipiprant, which the user is considering after experiencing side effects from finasteride and dutasteride. Another user mentions that setipiprant was ineffective in clinical trials.

The conversation discusses using topical dutasteride with a dermapen for hair loss treatment. The user is deciding between liposomal and mesosomal formulations for this purpose.

PRP treatments have been effective for the user, with a new recommendation of using a high-quality plasma kit once a year. The user seeks experiences with this specific PRP approach.

DUPA is considered more treatable than FAPD, as FAPD involves scarring that prevents hair regrowth. The user has started treatment with oral dutasteride and minoxidil, hoping for better results than previous treatments.

JXL069, also known as PP405, did not lead to hair regrowth after a year of testing. The lack of results may be due to formulation issues, leading to a final attempt with an improved vehicle.

PP405 is a new hair loss treatment showing early promise with a 20% hair density increase, but skepticism exists due to past failures of similar treatments like Pyrilutamide, RU58841, and Bimatoprost. Users debate its potential effectiveness, with some hopeful due to Google's involvement, while others urge caution without more evidence.

PP405 shows promise for hair follicle reactivation with minimal side effects. Users recommend continuing Minoxidil and Finasteride until more results are confirmed.

PP405 is expected to work for hair regrowth by reactivating stem cells in hair follicles, with FDA approval anticipated in 2027-28. Users express both optimism and skepticism about its effectiveness and the lengthy approval process.

PP405 is a safer alternative to JXL069 for hair loss treatment because it penetrates the skin effectively and degrades in the blood, avoiding systemic toxicity. JXL069, when forced into the body, can cause dangerous side effects like lactic acidosis due to its inability to degrade safely.

PP405, developed by Pelage Pharmaceuticals, can reactivate dormant hair follicle stem cells and increase hair growth by 20% in eight weeks, unlike minoxidil or finasteride. However, skepticism remains about its effectiveness and availability, with concerns about funding and the timeline for broader access.

Finasteride and Dutasteride will remain accessible in the EU despite objections from France and Belgium. Users discuss the ease of obtaining these medications in different countries and express relief and support for the EU's decision.

Recruitment for a verteporfin trial and a separate hair cloning trial using verteporfin and other methods is underway, with locations in Jordan, NYC, Beverly Hills, and Memphis. Dr. Bloxham is conducting the hair cloning trial, and interested participants are encouraged to contact him directly.

The conversation discusses purchasing Avodart (dutasteride) at a low price, with the OP using 1mg daily for hair loss. Users inquire about the source, and OP confirms buying from Oxford Pharmacy in the UK.

People are discussing their reactions if PP405 fails in phase 3 trials, with some expressing skepticism and others holding onto hope for future treatments like GT20029 and Breezula. Many mention continuing with existing treatments like minoxidil and finasteride, while others express disappointment and consider alternative solutions.

Pumpkin seed oil may increase hair count but not thickness, though its effectiveness is debated. Some suggest using topical finasteride or saw palmetto instead.